Antibody Drug Conjugates: Contract Manufacturing Market, 2014 - 2024

News provided by

Mar 05, 2014, 10:45 ET

DUBLIN, March 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/w2749d/antibody_drug) has announced the addition of the "Antibody Drug Conjugates: Contract Manufacturing Market, 2014 - 2024" report to their offering.

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The concept of Antibody drug conjugates (ADCs) is simple - a cytotoxic / chemotherapy drug is delivered to the target tissue through linking it with a monoclonal antibody. However, the practical challenge of manufacturing such complex and highly toxic molecules is huge.

The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this new class of therapeutic agents is gaining increased attention from both small and large pharmaceutical companies, in-house manufacturing capabilities for these molecules are rare. Most of the companies have a limited number of ADCs under development. Considering the utilisation rates are likely to be low in the near future, the investment required for setting up such high-containment biologic facilities is a huge financial risk.

As such, majority of the work is currently being outsourced to specialist CMOs focused on one or more areas of ADC manufacturing. The last one year has witnessed a surge in investments from the CMOs for facility expansions. Such investment decisions have been driven by an increase in the demand for ADC production services from drug developers. Although, there are only three marketed ADCs till date, a rich and growing pipeline is a very big opportunity for the contract manufacturers.

The 'ADC Contract Manufacturing Market, 2014-2024' report provides an extensive study of the contract manufacturing opportunity for this emerging class of therapeutics. The report covers various aspects and identifies the CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities.

Key Topics Covered:

1. PRELUDE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. ADC THERAPEUTICS: DEVELOPMENT OVERVIEW
5. MANUFACTURING OF ADCs: A MARKET OVERVIEW
6. CMOs: WORLDWIDE LANDSCAPE
7. PROFILES OF LEADING COMPANIES
8. MARKET SIZE AND FORECAST
9. SWOT ANALYSIS
10. INTERVIEW TRANSCRIPTS
11. CONCLUSION
12. LIST OF COMPANIES AND ORGANISATIONS
13. TABLES

Companies Mentioned: